Safaa Fellous
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Safaa Fellous has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Abdellah El Maghraoui
Rheumatology Office, Mohamed V University, Rabat, Morocco
1 shared publication Amina Bouraqadi
TB & Resp Dis Diagnost Ctr, Bab Khmiss, Sale, Morocco
1 shared publicationFadoua Allali
Mohammed Univ, Ibn Sina Univ Hosp, El Ayachi Hosp, Dept Rheumatol B, Rabat, Morocco
1 shared publication- Fadoua Allali
Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco
1 shared publication Hanan Rkain
Mohammed Univ, Ibn Sina Univ Hosp, El Ayachi Hosp, Dept Rheumatol B, Rabat, Morocco
1 shared publication- Hanan Rkain
Mohammed V Univ, Fac Med & Pharm, Physiol Lab, Exercise Physiol & Autonomous Nervous Syst Team, Rabat, Morocco
1 shared publication
Latest Publications
- 2 January 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (4) , 787-793
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry
The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann–Whitney and Kruskal–Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472–€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.
- 2 January 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (4) , 787-793
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry
The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann–Whitney and Kruskal–Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472–€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.
- Open Access
- 8 July 2020
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 36
Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report
Pre-extensively drug resistant tuberculosis (pre-XDR-TB) has been an area of growing concern, and posing a threat to global efforts of TB control. We report a case of PreXDR-TB spondylodiscitis with resistance to a Fluoroquinolone, in an immunocompetent patient under antibacillary treatment for pleural tuberculosis, managed with drug sensitivity-based second-line antituberculous drug regimen. Our case shows the challenges of the diagnostic and management of Drug-resistant TB spondylodiscitis.
- 8 July 2020
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 36
Open AccessPre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report
Pre-extensively drug resistant tuberculosis (pre-XDR-TB) has been an area of growing concern, and posing a threat to global efforts of TB control. We report a case of PreXDR-TB spondylodiscitis with resistance to a Fluoroquinolone, in an immunocompetent patient under antibacillary treatment for pleural tuberculosis, managed with drug sensitivity-based second-line antituberculous drug regimen. Our case shows the challenges of the diagnostic and management of Drug-resistant TB spondylodiscitis.